Plasmablastic lymphoma: A review of current knowledge and future directions

Bibliographic Information
Authors: Elyamany G.; Al Mussaed E.; Alzahrani A.M.
Journal: Advances in Hematology
Publisher: John Wiley and Sons Ltd
Publication Date: 2015
Volume / Issue: Volume 2015
Article No.: 315289
ISSN: 16879104
DOI: 10.1155/2015/315289
Scopus: View on Scopus
Document Type: Retracted
Access: All Open Access; Gold Open Access; Green Open Access
Authors and Affiliations
Elyamany G., Department of Pathology and Blood Bank, Prince Sultan Military Medical City, P.O. Box 7897, Riyadh, 11159, Saudi Arabia, Department of Hematology, Theodor Bilharz Research Institute, Egypt; Al Mussaed E., Hematopathology Division, Department of Basic Science, College of Medicine, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia; Alzahrani A.M., Department of Oncology, Prince Sultan Military Medical City, Saudi Arabia
Abstract
Plasmablastic lymphoma (PBL) is an aggressive subtype of non-Hodgkin's lymphoma (NHL), which frequently arises in the oral cavity of human immunodeficiency virus (HIV) infected patients. PBL shows diffuse proliferation of large neoplastic cells resembling B-immunoblasts/plasmablasts, or with plasmacytic features and an immunophenotype of plasma cells. PBL remains a diagnostic challenge due to its peculiar morphology and an immunohistochemical profile similar to plasma cell myeloma (PCM). PBL is also a therapeutic challenge with a clinical course characterized by a high rate of relapse and death. There is no standard chemotherapy protocol for treatment of PBL. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like regimens have been the backbone while more intensive regimens such as cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, high-dose cytarabine (CODOX-M/IVAC), or dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) are possible options. Recently, a few studies have reported the potential value of the proteasome inhibitor bortezomib and thalidomide in PBL patients. The introduction of genes encoding artificial receptors called chimeric antigen receptors (CARs) and CAR-modified T cells targeted to the B cell-specific CD19 antigen have demonstrated promising results in multiple early clinical trials. The aim of this paper is to review the recent advances in epidemiology; pathophysiology; clinical, pathologic, and molecular characteristics; therapy; and outcome in patients with PBL. © 2015 Ghaleb Elyamany et al.
Keywords
CD19 antigen; chimeric antigen receptor; cyclophosphamide; cytarabine; doxorubicin; etoposide; ifosfamide; methotrexate; prednisone; vincristine; autologous hematopoietic stem cell transplantation; B lymphocyte; biopsy; cancer combination chemotherapy; cancer diagnosis; cancer epidemiology; cancer prevention; cancer prognosis; cell proliferation; differential diagnosis; drug megadose; fine needle aspiration biopsy; human; immunophenotyping; overall survival; pathogenesis; pathophysiology; plasmablastic lymphoma; priority journal; Review; T lymphocyte; treatment outcome
Citation Information
Scopus Citations: 32
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
